First Multi-Centre Data on OncoSil Shows Promising Results

OncoSil Medical Limited (ASX: OSL) presented the first multi-centre data on the use of OncoSil in treating patients with metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer. The study involved 14 patients from Australia and the United Kingdom who received OncoSil in addition to standard-of-care systemic chemotherapy. The implantation of OncoSil into the primary pancreatic tumor was found to be safe and feasible.

Encouraging clinical outcomes were observed, including a 100% Local Disease Control Rate (LDCR) at 3 months after implantation and a median overall survival of 13.9 months from the start of chemotherapy. Most cases of cancer progression occurred at distant sites rather than locally. The median overall survival for patients treated with OncoSil was higher than the median survival reported in Phase III trials using standard chemotherapy alone. Although OncoSil is not currently approved for metastatic pancreatic cancer, these results suggest potential clinical benefits for patients in terms of local tumor control and overall survival.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com